Volume 28, Number 1—January 2022
Dispatch
SARS-CoV-2 RNA Shedding in Semen and Oligozoospermia of Patient with Severe Coronavirus Disease 11 Weeks after Infection
Table 2
RT-PCR and serologic test results for participant 1 who was infected with SARS-CoV-2 in longitudinal prospective coronavirus disease cohort study, New York, USA*
Days after symptom onset | Sample | PCR result, Ct | Binding antibody EC50, NP/S | Neutralizing antibody IC50 | T cell reactivity against M protein, IFN-γ‒secreting T cells/million PBMCs† |
---|---|---|---|---|---|
72 | Saliva | Negative | |||
72 |
Blood |
Negative |
1,351/3,728 (modest) |
(modest) |
|
78 |
Saliva |
Negative |
|||
78 |
Stool |
Negative |
|||
78 |
Blood |
Negative |
1,756/5,680 (modest) |
(modest) |
|
81 |
Semen |
Positive, 34.79 |
|||
81 |
Blood |
NT |
>130 (strong) |
||
81 |
Saliva |
Negative |
|||
101 |
Semen |
Negative |
|||
101 |
Saliva |
Negative |
|||
101 |
Stool |
Negative |
|||
169 |
Saliva |
Negative |
|||
169 | Stool | Negative | |||
169 | Semen | Negative |
*Ct, cycle threshold; EC50, concentration half of the maximum effect; IC50, half-maximal inhibitory concentration; IFN, interferon; NP, nucleocapsid protein; NT, not tested; PBMCs, peripheral blood mononuclear cells; S, spike protein; SARS-CoV 2, severe acute respiratory syndrome coronavirus 2.